Introduction {#sec0001}
============

Human rhinovirus (HRV) is the most commonly detected respiratory virus after hematopoietic cell transplantation (HCT) in both the upper and lower respiratory tract [@bib0001], [@bib0002]. Although rare, once virologically confirmed lower respiratory tract infection (LRTI) has developed, mortality rates due to HRV appear to be high (21% to 41%) and even similar to those seen with other respiratory viruses including influenza, respiratory syncytial virus (RSV), and parainfluenza viruses (PIVs) [@bib0003], [@bib0004], [@bib0005]. Risk factors associated with LRTI in this population have been defined for RSV, PIVs, influenza, and human metapneumovirus (hMPV) [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010], which include lymphopenia, use of high--dose steroids, and conditioning regimen; this has not been done systematically in HCT recipients presenting with HRV upper respiratory tract infection (URTI). In a study of HRV infection that included both HCT recipients and patients with hematologic malignancies, factors more likely to be present in patients with LRTI included inpatient status, lymphopenia, and hypoalbuminemia [@bib0011]. Of note, not all cases of LRTI were virologically confirmed in this study, and the analysis was not conducted in a time--dependent manner. Furthermore, several key factors including viral load were not evaluated in this study.

In the present study we aimed to identify specific risk factors for progression to LRTI in a cohort of patients presenting with URTI. We then developed a risk score for disease progression to help clinicians risk stratify patients who may benefit from more intensive monitoring and follow-up. Ultimately, identification of high--risk patients will be important for clinical trial design that will require defining an enriched cohort at high risk for LRTI that may benefit from potential interventions.

Methods {#sec0002}
=======

Patients and Data Collection {#sec0003}
----------------------------

We retrospectively identified all HCT patients who underwent transplant between January 1, 2009 and April 1, 2016, at Fred Hutchinson Cancer Research Center. Subjects were eligible for inclusion in the study if positive for HRV from the upper respiratory tract post-transplant. Patients with HRV infection before transplant were excluded.

Clinical data were collected from databases and supplemental review of the medical record. This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center. Subjects signed informed consent permitting the use of data for research.

HRV Case Identification {#sec0004}
-----------------------

Respiratory tract samples collected as part of routine clinical care from adult and pediatric patients with respiratory symptoms were tested for 12 respiratory viruses by real-time reverse-transcriptase PCR (RT-qPCR) assays, including RSV, hMPV, influenza viruses A and B, PIVs 1 to 4, adenovirus, human coronaviruses, HRV, and human bocavirus. RT-qPCR with this multiplex panel was performed on all respiratory samples during the time period of this study. The RT-qPCR cycle threshold (CT) was used as a proxy for viral load, with lower CT indicating a higher viral load. CT values were analyzed in quartiles as well as above and below the median.

Definitions {#sec0005}
-----------

URTI was defined as a positive HRV PCR result from an upper tract sample (nasopharyngeal swab or wash) only from a symptomatic patient, without any radiographic abnormalities. LRTI was defined as a positive lower tract sample (bronchoalveolar lavage \[BAL\], lung biopsy, or autopsy specimen) with or without radiographic abnormality (proven or probable LRTI, respectively) or a positive upper tract sample with radiographic abnormality (possible LRTI). Both chest x-rays and chest computed tomography results were included if completed within 2 weeks of last positive HRV date. Lower tract sample results were included up to 3 months from URTI date. The day of LRTI diagnosis was defined as the date when HRV was detected in the lower tract specimen (in proven/probable LRTI) or the date the radiographic abnormality was detected (in possible LRTI). Patients who met criteria for LRTI within 2 days of URTI were considered to have LRTI at presentation and were not included in the progression analyses. An HRV illness event was considered to be a new event if ≥12 weeks elapsed between 2 positive samples or if there were ≥2 negative HRV samples between 2 HRV positive samples.

Statistical Analysis {#sec0006}
--------------------

The probability of progression from upper to lower HRV infection was estimated using cumulative incidence, treating death as a competing risk event. Factors associated with progression to LRTI were evaluated using Cox regression models.

The following variables were considered potential predictors of progression: patient age; sex; donor type; cell source; year transplant performed; conditioning regimen; most recent WBC count; neutrophil, lymphocyte, monocyte, and platelet counts before HRV infection (within 2 weeks); lowest albumin level in the 2 weeks before HRV infection; highest daily steroid dose in the 2 weeks before HRV infection; pretransplant lung function; HCT-specific comorbidity index (HCT-CI) [@bib0012]; time from transplant to HRV infection; HRV CT values, acute and chronic graft-versus-host-disease; and recipient and donor cytomegalovirus (CMV) serostatus. Recipient and donor statin use was defined as previously reported [@bib0013].

All covariates with *P* ≤ .2 in the univariable analyses were candidates for inclusion in the multivariable Cox regression models. Initially, any variable was retained in the multivariable model if its *P* ≤ .1 in the full model. The multivariable model was further reduced for constructing the risk score by evaluating the change in the bootstrapped optimism corrected concordance statistic (c-statistic) when each factor was removed from the full model [@bib0014]. The bootstrapped c-statistic was based on 100 replications. Those factors having little impact on the c-statistic were removed. Score point contributions were developed using the hazard ratios from the final multivariable model. Hazard ratios were rounded to the nearest integer and scaled such that the maximum achievable score was 100. The risk score for each subject was calculated based on their covariate values and the associated points given. Curves were constructed to examine impact of shifting cut points of the risk score on sensitivity and specificity rates. Cumulative incidence curves for progression to LRTI for score values above (positive predictive value) and below (negative predictive value) a series of binary cut-off values as well as within categorized ranges of scores were evaluated and compared using log-rank tests and Gray\'s test. Subjects with missing values for albumin, CMV serostatus, and recipient statin status were excluded from univariable and multivariable analyses.

Statistical significance was defined as 2-sided *P* \< .05. SAS version 9.4 TS1M3 (SAS Institute, Inc., Cary, NC) and R version 3.3.0 [@bib0015] were used for statistical analyses.

Results {#sec0007}
=======

Cohort Description {#sec0008}
------------------

Among 3445 patients undergoing HCT during the study time period, 732 (21%) were positive for HRV from at least 1 respiratory site ([Figure 1](#fig0001){ref-type="fig"} ), resulting in 782 HRV illness events. Of these, 665 events (85%) represented URTI at presentation, whereas 15% of events involved presentation with LRTI. Of 665 URTI events, 588 events had complete data for all covariates and were included in the progression analyses. Among subjects with multiple HRV URTI events, the median time between events was 302 days (interquartile range \[IQR\], 140 to 515). In subjects with URTI at presentation, median age was 42.8 years (IQR, 22.2 to 57.7), and there was a slight male predominance (59%) ([Table 1](#tbl0001){ref-type="table"} ). Seventeen percent of URTI events (100/588) progressed to LRTI with 28 (28%) proven LRTI events and 72 (72%) possible LRTI events. No probable LRTI events occurred. Most HRV URTI events occurred in recipients of allogeneic HCT (438/588; 74%); 19% (84/438) of events progressed to LRTI in this group with 25 (30%) proven LRTI events and 59 (70%) possible LRTI events. Median time to progression from URTI to LRTI was 12 days for all events (IQR, 7 to 22) and 12 days for allogeneic subjects only (IQR, 8 to 24) ([Figure 2](#fig0002){ref-type="fig"} A,B). Of subjects with possible LRTI events, none had a BAL performed.Figure 1Standards for Reporting of Diagnostic Accuracy (STARD) flowchart demonstrating the score performance on the study population.Figure 1.Table 1Demographics (N = 588)Table 1CovariatesCategoriesValueAge at transplant, yrMedian (IQR)42.8 (22.2-57.7)Age at transplant\<21 yr140 (24)21-60 yr330 (56)61+ yr118 (20)Transplant year1992-2010237 (40)2011-2015351 (60)SexFemale239 (41)Male349 (59)RaceNonwhite149 (25)White397 (68)Unknown42 (7)Cell sourcePBSC418 (71)BM/cord170 (29)Donor typeAllogeneic/unrelated438 (74)Autologous150 (26)Conditioning regimenMyeloablative  +  high TBI158 (27)Myeloablative ± low TBI287 (49)Non-myeloablative143 (24)% FEV~1~/FVC before HRV URTI≤7089 (15)\>70427 (73)Missing72 (12)% TLC before HRV URTI≤8074 (13)\>80363 (62)Missing151 (26)WBC count closest to HRV URTI, 10^6^ cells/L≤100060 (10)\>1000528 (90)Lymphocyte count closest to HRV URTI, 10^6^ cells/L≤10056 (10)\>100532 (90)Neutrophil count closest to HRV URTI, 10^6^ cells/L≤10043 (7)\>100545 (93)Monocyte count closest to HRV URTI, 10^6^ cells/L≤10074 (13)\>100514 (87)Platelet count closest to HRV URTI, 10^6^ cells/L\<10,0008 (1)≥10,000580 (99)IVIG given before HRV URTINo545 (93)Yes40 (7)Missing3 (1)Steroid use before HRV URTI, mg/kg/day0305 (52)\>0 to \<1236 (40)≥1 to \<231 (5)≥216 (3)Any previous HRV eventNo453 (77)Yes135 (23)Viral copathogens at time of HRV URTINo531 (90)Yes57 (10)Time to URTI from transplant, days0-100257 (44)101-365125 (21)365+206 (35)Albumin before HRV URTI, g/dL≤381 (14)\>3507 (86)HCT-CI score0131 (22)1-2197 (34)≥3248 (42)Missing12 (2)Donor statin useNo124 (21)Yes8 (1)Auto150 (26)Unknown306 (52)Recipient statin useNo528 (90)Yes60 (10)Recipient CMV serostatus--269 (46)+319 (54)Donor CMV serostatus--377 (64)+209 (36)Missing2 (0)HRV CT valuesMedian (IQR)25.7 (22.1-30.7)Acute GVHDGrades 0-I78 (13)Grades II-IV350 (59)None160 (27)Chronic GVHDNo177 (30)Yes411 (70)[^1]Figure 2Cumulative incidence curves for progression to LRTI in all subjects (A) (log rank test *P* = .18) and in allogeneic recipients only (B) (log rank test *P* = .91), stratified by event number.Figure 2.

Risk Factors for Progression to LRTI {#sec0009}
------------------------------------

In univariable analysis of all events, donor type, conditioning regimen, prior HRV events, steroid use, albumin level, recipient statin use, recipient CMV serostatus, and most recent WBC count, and neutrophil, lymphocyte, and monocyte counts were sufficiently associated with progression to LRTI to be considered for inclusion in a multivariable model ([Table 2](#tbl0002){ref-type="table"} ). Notably, the presence of viral co-pathogens, pulmonary function, or intravenous immunoglobulin, and HRV CT values in the upper tract sample were not associated with progression to LRTI. Univariate and multiple multivariate models for risk factors for progression to proven LRTI only are shown in Supplementary [Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"}.Table 2Univariable Cox Regression Analysis of Risk Factors for Any LRTI (N = 588)Table 2CovariatesCategoriesHR (95% CI)*P*Age at transplant\<21 yr121-60 yr.82 (.51-1.33).41661+ yr1.25 (.72-2.17).42Transplant year1992-201012011-2015.91 (.61-1.36).655SexFemale1Male1.16 (.77-1.74).479RaceNonwhite1White1.12 (.70-1.78).632Unknown.72 (.28-1.90).51Cell sourcePBSC1BM/cord1.35 (.90-2.04).151Donor typeAutologous1Allogeneic/unrelated1.85 (1.08-3.16).024Conditioning regimenMyeloablative ± TBI1Non-myeloablative1.68 (1.11-2.54).014% FEV~1~/FVC before HRV URTI≤701\>70.85 (.49-1.47).559% TLC before HRV URTI≤801\>801.24 (.63-2.41).536WBC count closest to HRV URTI, 10^6^ cells/L\>10001≤10001.39 (.78-2.49).266Lymphocyte count closest to HRV URTI, 10^6^ cells/L\>1001≤1002.13 (1.26-3.59).005Neutrophil count closest to HRV URTI, 10^6^ cells/L\>1001≤1001.91 (1.04-3.49).036Monocyte count closest to HRV URTI, 10^6^ cells/L\>1001≤1002.01 (1.24-3.26).004Platelet count closest to HRV URTI, 10^6^ cells/L≥10,0001\<10,0001.55 (.38-6.30).537IVIG given before HRV URTINo1Yes1.42 (.72-2.82).315Steroid use before HRV URTI, mg/kg/day01\>0 to \<11.09 (.71-1.67).686≥1 to \<21.78 (.84-3.77).132≥23.01 (1.29-7.04).011Any previous HRV eventNo1Yes1.35 (.87-2.09).178Viral copathogens at time of HRV URTINo1Yes1.28 (.70-2.35).416Time to URTI from transplant, days0-1001101-3651.42 (.89-2.28).142365+.80 (.50-1.29).367Albumin before HRV URTI, g/dL≤31\>3.50 (.31-.81).004HCT-CI score0-21≥3.70 (.47-1.06).093Missing.41 (.06-2.94).374Donor statin useNo1Yes1.16 (.28-4.90).835Unknown.81 (.51-1.28).359Recipient statin useNo1Yes1.67 (.96-2.89).068Acute GVHD as time-dependentGrades 0-I1Grades II-IV1.52 (1.01-2.28).046Chronic GVHD as time-dependentNo1Yes1.18 (.79-1.75).415Recipient CMV serostatus--1+1.90 (1.25-2.89).003Donor CMV serostatus--1+1.22 (.82-1.83).332HRV CT valuesBelow lower quartile1Lower quartile to median1.22 (.69-2.16).487Median to upper quartile1.04 (.58-1.87).896Above upper quartile1.09 (.61-1.95).77HRV CT values≤ lowest 10th percentile1\> lowest 10th percentile.97 (.50-1.86).923[^2][^3]

Candidate variables from univariable analysis were evaluated in a multivariate model. Covariates were added sequentially and c-statistic calculated for each model until the optimal model with the highest c-statistic was achieved ([Table 3](#tbl0003){ref-type="table"} ). In the final model the c-statistic was .676, whereas the optimism corrected c-statistic was .656.Table 3Multivariable Analyses of Risk Factors for LRTI in All SubjectsTable 3CovariatesCategoriesHR (95% CI)*P*Score WeightAlbumin\>31≤31.65 (.99-2.76).05611Recipient CMV serostatus-1+1.79 (1.17-2.73).00712Donor typeAutologous1Allogeneic/unrelated2.08 (1.22-3.58).00814Any previous HRV eventsNo1Yes1.67 (1.05-2.65).0312Lymphocyte count closest to HRV URTI, 10^6^ cells/L\>1001≤1002.39 (1.33-4.29).00416Recipient statin useNo1Yes2.06 (1.16-3.64).01314Steroid use before HRV URTI, mg/kg/day0 to \<11≥1 to \<21.73 (.84-3.58).13912≥22.91 (1.27-6.69).01220

Score Development and Performance {#sec0010}
---------------------------------

A risk score was developed as described and weighted contributions of each factor are shown in [Table 3](#tbl0003){ref-type="table"}. Specificity and sensitivity of score cut--offs for development of LRTI in the entire cohort and the allogeneic cohort are shown in [Figure 3](#fig0003){ref-type="fig"} A and B, respectively. Among all subjects the score cut-off with the highest sensitivity (57%) and specificity (71%) was 27, corresponding to a positive predictive value of 28% and a negative predictive value of 89% in this population. Cumulative incidence curves for progression to LRTI in all subjects, stratified by above and below a range of binary score cut--offs are shown in [Figure 4](#fig0004){ref-type="fig"} A and B, representing positive and negative predictive values for a given cut--off, respectively. Cumulative incidence of progression to LRTI for the ≥27 group was 28% versus 11% in the \<27 group (log-rank and Gray\'s test both *P* \< .001). [Figure 4](#fig0004){ref-type="fig"}C illustrates the ability of the score to stratify the population into 4 mutually exclusive levels of risk. Cumulative incidence of progression to LRTI was as follows: scores \< 16 (9%), 16 to \<27 (13%), 27 to \<46 (24%), and ≥46 (43%) (log-rank test and Gray\'s test both *P* \< .001). The weighted risk score was applied to the allogeneic subgroup only and cumulative incidence curves above and below the 27 cut--off are shown [Figure 5](#fig0005){ref-type="fig"} A. For scores ≥ 27 the cumulative incidence was 29% versus 13% for scores \< 27 (log-rank test and Gray\'s test *P* \< .001). The score was also applied to the whole cohort and evaluated with proven LRTI only as the outcome. [Figure 5](#fig0005){ref-type="fig"}B shows the cumulative incidence curves above and below 27 for progression to proven LRTI only. For scores ≥ 27 the cumulative incidence was 9% versus 3% for scores \< 27 (log-rank test and Gray\'s test *P* = .001).Figure 3Specificity and sensitivity calculations for weighted score for progression to LRTI in all subjects (A) and in allogeneic subjects only (B).Figure 3.Figure 4Cumulative incidence curves for progression to LRTI in all subjects, stratified by above (A) and below (B) a range of binary score cut-offs, representing positive and negative predictive values for a given cut-off, respectively. Log-rank and Gray\'s test comparing the ≥27 versus \<27 groups both *P* \< .001. Cumulative incidence curves for progression to LRTI in all subjects, stratified into 4 mutually exclusive levels of risk (C; log-rank test and Gray\'s test *P* \< .001).Figure 4.Figure 5Cumulative incidence curves of progression to LRTI in allogeneic recipients only (A) and of progression to proven LRTI in all subjects (B), stratified above and below score of 27. Log-rank test and Gray\'s test *P* \< .001 for both curves.Figure 5.

Discussion {#sec0011}
==========

In this large retrospective study of HCT recipients infected with HRV in the upper respiratory tract, we established risk factors and developed a risk score for progression to LRTI. To our knowledge this is the largest and statistically most rigorous study to systematically examine patients specifically presenting with URTI to determine the risk of subsequent LRTI. In multivariable models for any LRTI event in all subjects, significant risk factors identified include allogeneic transplant, prior HRV URTI events, lymphocyte count \< 100 × 10^6^ cells/L, recipient statin use, recipient CMV serostatus, and steroid use ≥ 2 mg/kg/day. We further characterized risk factors for progression by calculating the change in the bootstrapped optimism corrected c-statistic for each risk factor and developed an optimized model for risk prediction. Using this model we developed a weighted score and describe the performance characteristics of the score at various cut--offs. The risk score presented in this article is a novel tool with potential to help risk stratify patients for clinical care and future clinical trials.

HRVs have recently been recognized as significant pathogens that can cause severe disease and poor outcomes in certain high risk groups, including infants, pregnant women, asthmatics, hospitalized adults, and immunocompromised children and adults [@bib0001], [@bib0003], [@bib0004], [@bib0011], [@bib0016], [@bib0017]. Once HRV LRTI has developed in HCT recipients, mortality rates are comparable with those associated with RSV, influenza, and PIV [@bib0003]. In a study of HRV infection that included both HCT recipients and patients with hematologic malignancies, factors more likely to be present in patients with LRTI included inpatient status, lymphopenia, and hypoalbuminemia [@bib0011]. In HCT recipients alone from the same center, hypoalbuminemia, and isolation of respiratory co-pathogen were associated with LRTI in multivariable models [@bib0004]. These analyses, although not done in a time-dependent manner, are similar to findings in the present study, in which lymphopenia and hypoalbuminemia were associated with progression to LRTI. We evaluated co-pathogens in the upper respiratory tract as a risk factor and did not find an association with LRTI.

Lymphopenia has been associated with progression to LRTI for other respiratory viruses including PIVs, RSV, hMPV, and influenza [@bib0006], [@bib0007], [@bib0009], [@bib0010], [@bib0018], [@bib0019], and was also more common in HRV LRTI subjects in a prior study [@bib0004]. Monocytopenia has not been evaluated systematically in prior respiratory virus progression studies, although there was a trend toward significance for hMPV [@bib0008], and monocytopenia was associated with mortality in HCT recipients with HRV and RSV LRTI [@bib0003], [@bib0020]. The relative role of monocytes over lymphocytes in progression of disease is not understood, and most studies have not evaluated both cell types concurrently. A potential mechanism of inflammatory and immune modulation via HRV induced monocytic cell directed CXL10 and IFN-γ release is plausible [@bib0021].

Steroid use is a well described risk factor for progression to LRTI for many respiratory viruses [@bib0006], [@bib0008], [@bib0009], [@bib0018], and higher doses of ≥2 mg/kg/day were associated with HRV LRTI in the present study. Of note, high--dose steroids are no longer frequently used for graft--versus--host disease treatment at our institution, as is reflected in the low frequency of use (3%) in this cohort. However, even lower dose steroids (≥1 to 2 mg/kg/day) showed a trend toward significance in the multivariable models, and this was included in the weighted score. Other centers may have higher rates of high--dose steroid use and should still be able to apply the score to their patient population.

Prior post-transplant HRV URTI infection was associated with increased risk of LRTI, an interesting and somewhat unexpected finding suggesting an effect of the cumulative burden of HRV infections, perhaps by mediating inflammatory responses that increase the likelihood of LRTI development. For parainfluenza viruses, URTI without LRTI is associated with late airflow decline, and a similar pathway may be at play for HRV infections [@bib0022]. Although it is possible we overestimated new events, our definition of \>12 weeks between events was chosen given our recent surveillance data showing the median duration of HRV shedding in HCT recipients is 9.5 days (range, 2 to 89) [@bib0023]. Given the long duration between events in the present study (median, 302 days; IQR, 140 to 515), we do not believe we are capturing prolonged viral shedding but rather truly new viral events.

Recipient CMV serostatus was associated with increased risk of LRTI, a novel finding for respiratory virus disease severity. CMV has a profound impact on the immune system in both immunocompetent and immunosuppressed individuals and known to have immunosuppressive effects [@bib0024], [@bib0025], [@bib0026]. It is well known to affect nonrelapse mortality in HCT patients [@bib0027]. CMV has also been shown to increase the risk of other viruses after HCT; however, the mechanisms are poorly understood. That CMV was associated with progression in this study is plausible but the results should be validated in a different cohort, and further studies are needed to elucidate the mechanism.

Recipient statin use as a risk factor for HRV LRTI is also an intriguing finding and corroborates prior results from a separate cohort at our center that demonstrated a trend toward association between recipient statin use and all respiratory viral infections and LRTIs [@bib0013]. Statins may act as immunosuppressants via direct inhibition of induction of MHC-II expression by IFN-γ and thus leading to reduced T cell activation [@bib0028] and may also have an effect of type I IFN receptor signaling in monocytes in the setting of HRV challenge, leading to reduced inflammatory response [@bib0029]. The role of statins on HRV progression should be validated in other cohorts and evaluated for other respiratory virus infections independently.

We evaluated the impact of HRV viral load and found no association with progression to LRTI. CT value as a surrogate for viral load has limitations given the diversity of HRV genotypes and the resulting differences in amplification efficiency using RT-qPCR assays with a consensus HRV primer and probe set. RT digital PCR has been recently shown to provide more precise quantification [@bib0030]. However, even when evaluating the extreme highest viral load group (CT values in the lowest 10th percentile), no effect was seen. In lung transplant recipients, higher HRV viral load was associated with increased symptoms associated with LRTI [@bib0031]. In immunocompetent pediatric patients, viral load was associated with disease severity in older but not younger children [@bib0032] and was also associated with higher rates of viremia and oxygen use [@bib0033]. The variable role of viral load in studies to date suggest both limitations in capturing accurate viral loads from clinical samples such as was done in our study and that other host factors including immune responses may be an important player in progression to LRTI and other clinical outcomes. Additionally, HRV species were not evaluated in the present study, and data have suggested HRV-C may be associated with worse outcomes, especially in children [@bib0034], [@bib0035]. The presence of viral co--pathogens in the upper respiratory tract was not associated with progression to HRV LRTI.

To provide clinical applicability for our findings, we developed weighted risk scores for progression to LRTI using methodology that allows for multiple sampling within the dataset to develop an optimized model [@bib0014]. Our final model showed an acceptable but not robust c-statistic of .656. Using this model we developed a weighted score and show specificity and sensitivity calculations for a range of score cut--offs, as well as cumulative incidence curves stratified by score cut--offs and within mutually exclusive score ranges. Maximum sensitivity and specificity was demonstrated at a score cut--off of 27; however, optimal score cut--off depends on the ultimate application of the score. For example, if the risk score is used for patient risk stratification for interventional clinical trials, a score cut--off with higher sensitivity and negative predictive value may be desirable.

Sample size limited our ability to extensively evaluate proven LRTI, which for other respiratory viruses (RSV and PIV) has been associated with worse clinical outcomes [@bib0036], [@bib0037]. In several separate multivariate models, however, risk factors for progression to proven LRTI were similar (low albumin, low monocyte count, and high--dose steroids). We applied our risk score to the proven LRTI outcome only, and subjects with a risk score higher than 27 were associated with proven LRTI. With a larger sample size a separate risk score for proven LRTI could be developed, although it is likely that risk factors would remain similar. Probable LRTI could represent contamination from the upper respiratory tract during the BAL procedure; however, there were no cases of probable LRTI in our cohort.

Although our analyses used an accepted resampling methodology (bootstrapping), ultimately a multicenter study is needed for validation of the score, especially given differences in clinical practices including the use of high--dose steroids. An immunodeficiency scoring index was developed for allogeneic HCT recipients with RSV infection to predict LRTI and RSV associated mortality [@bib0010]; the score was also applied to influenza [@bib0019]. Similar variables were evaluated in the present study and were not associated with the outcome with the exception of steroid use, suggesting rhinovirus progression may be determined by a unique set of risk factors compared with other respiratory viruses and a separate risk score is needed.

This study has strengths and limitations. First, this is a retrospective study in which data collection, including viral load determination, was dependent on clinical databases. However, at our institution data from transplant recipients is prospectively recorded in a central database, and we also conducted detailed chart review on every patient to obtain additional clinical data. Second, we captured both proven LRTI (HRV detected in the lower respiratory tract with abnormal imaging) and possible LRTI (HRV detected in the upper respiratory tract with abnormal imaging but no lower tract sampling). At our institution the use of BAL is based on standardized protocols outlining that BAL should be performed in HCT recipients with a respiratory virus detected in the upper respiratory tract and abnormal chest imaging. However, ultimately the need for BAL is determined by the attending physician, and thus some proven or probable cases (HRV detected in the lower respiratory tract without abnormal imaging) may have been missed. By including both proven and possible LRTI events (no probable events occurred), this effect is mitigated; however, proven LRTI may be the more relevant outcome given the mortality rates seen with proven HRV LRTI and the differences in outcomes observed in proven LRTI for PIV and RSV [@bib0003], [@bib0036], [@bib0037]. Regardless, many institutions do not routinely use BAL for virologic confirmation, and thus our results for any LRTI events can be broadly applicable. Finally, our data include both allogeneic and autologous HCT recipients, and there may be a bias toward increased testing in the allogeneic group and therefore more LRTI events captured. However, the risk score performed reasonably well in the allogeneic subgroup.

We were not able to evaluate risk factors for HRV LRTI cases without any co--pathogens in the lower respiratory tract separately. In a prior study the presence of co--pathogens was not associated with mortality in HCT recipients with proven HRV LRTI, suggesting that HRV detection in the lower tract is pathogenic regardless of co--pathogens and therefore making any proven HRV LRTI an important endpoint [@bib0003]. Because BAL was not done in possible LRTI cases, it is plausible that other pathogens are contributing to the radiographic changes, and thus these are not true LRTI events. However, as stated above, in clinical practice BAL is often not attempted, and co--pathogen data are not available, yet patients are considered to have LRTI. Thus, we included possible LRTI as an endpoint. Several epidemiologic studies and clinical trials of respiratory viruses in HCT recipients have used definitions of LRTI that include possible cases [@bib0004], [@bib0010], [@bib0035], [@bib0038], [@bib0039], [@bib0040], [@bib0041], [@bib0042].

In summary, we describe the risk factors and development of a risk score for progression to LRTI in a large cohort of HCT recipients with HRV URTI. The risk score proposed may have implications for risk stratifying patients for more intense clinical monitoring. Additionally, risk stratification will help inform the design of future randomized clinical trials of novel therapeutics, including the growing field of virus specific T cells, which are currently being evaluated for other respiratory viruses including PIV and hMPV [@bib0043], [@bib0044].
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[^1]: Values are n (%) unless otherwise defined. PBSC indicates peripheral blood stem cells; BM, bone marrow; TBI, total body irradiation; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; TLC: total lung capacity; IVIG, intravenous immunoglobulin.

[^2]: HR indicates hazard ratio; CI, confidence interval.

[^3]: \*Autologous HCT recipients excluded from the analysis.
